CGRP Forum is made possible thanks to support from AbbVie, Organon and Pfizer, all of whom have no influence or control over editorial content. More information is available here »
At the 68th Annual Scientific Meeting of the American Headache Society (4-7 June, Orlando, USA), presentations included latest research with anti-CGRP therapies and promising results with investigational agents targeting emerging mechanisms linked to migraine.
Over half of patients with migraine-related cognitive symptoms reported improvements in all domains in the prospective real world INFUSE study of 190 participants who had failed on at least one previous CGRP-targeted preventive therapy. At baseline, 93.7% (178/190) reported brain fog, 78.9% (150/190) reported difficulty making decisions, 82.6% (157/190) reported difficulty reading, and 82.6% (157/190) …
Read more »Results of the Phase 3, open label UNCHAINED study have shown that adding atogepant 60 mg to onabotulinumtoxinA 155-200U in patients with chronic migraine was associated with consistent increases in cardinal and complete migraine symptom-free days over 24 weeks of treatment (NCT05216263). In the modified intention-to-treat population of 72 patients, incremental symptom burden days from …
Read more »Primary care physicians (PCPs) account for only one in five gepant prescriptions despite seeing the majority of patients with migraine, report US headache specialists. In a study examining gepant prescribing at the University of Washington, a tertiary academic medical centre with dedicated headache specialists and multiple primary care clinics, 145 patients were identified who were …
Read more »Exposure to CGRP mAbs during pregnancy is associated with a 50% increased risk of spontaneous abortion before 20 weeks, according to results of a Canadian retrospective cohort study of 11,819 pregnancies in women with pregestational migraine. Of these, 319 (2.7%) were exposed to anti-CGRP mAbs (+/-propranolol), 299 to propranolol (without anti-CGRP mAb), and 11,201 to neither, …
Read more »The PACAP-targeting monoclonal antibody, bocunebart, significantly reduces monthly migraine days (MMDs), according to results of the Phase 2b, dose finding PROCEED trial with patients who had failed at least 1 to 4 different migraine preventive medications in the previous 10 years and had at least 4 migraine days per month for each month in the …
Read more »Encouraging Phase 1 pharmacokinetic data for the investigational TRPM8-targeting agent, elismetrep, have shown more rapid absorption with a novel liquid-filled softgel capsule (LSGC) than with the dry-filled capsule (DFC) formulation used in the Phase 2b study of the agent.1 In the study, median time to maximum concentration [Tmax] was 1 hour with the LSGC formulation …
Read more »
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
